|作者：||De Felice F, Pranno N, Marampon F, Musio D, Salducci M, Polimeni A, Tombolini V|
1Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Rome, Italy. Electronic address: firstname.lastname@example.org.
2Department of Oral and Maxillo Facial Sciences, Policlinico Umberto I "Sapienza" University of Rome, Italy.
3Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Rome, Italy.
4Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
|刊名：||Critical reviews in oncology/hematology, 2019, Vol.138 , pp.60-69|
|关键词：||Benefit; Glioblastoma; Immune check-point; Immunotherapy; Survival;|
|原始语种摘要：||Glioblastoma multiforme (GBM) represents one of the main frequent and aggressive primary brain neoplasms among adults worldwide. Despite a first-line multimodal treatment, including radical surgery and adjuvant radiation therapy with concomitant temozolomide-based chemotherapy, GBM prognosis continues to be unfavourable. During this decade, different research groups have explored immune check-point inhibitors role in order to improve response to therapy and subsequently prolong survival rate. The aim of this review was to analyze published literature to support immune check-point inhibitors use in the management of patients with GBM diagnosis. The hope was to help physicians for better decision-making.|